Paper Details

  1. Home
  2. Paper Details

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Author: FieldStephen K, GiembyczMark A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Roflumilast, a selective phosphodiesterase 4 inhibitor, is now approved in Europe for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis. Clinical trials have shown that roflumilast improves lung function and reduces exacerbations in patients with COPD. Although gastrointestinal upset and headache are common side effects, roflumilast offers an oral option for COPD management.
Paper Details　
Original Abstract of the Article :
In April 2010, the European Medicines Agency Committee for Medicinal Products for Human Use recommended approval of roflumilast, a selective phosphodiesterase 4 inhibitor, for the "maintenance treatment of severe chronic obstructive pulmonary disease (COPD, FEV(1) postbronchodilator less than 50% pr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915539/

データ提供：米国国立医学図書館（NLM）

Roflumilast: A New Oasis for COPD Patients

The world of chronic obstructive pulmonary disease (COPD) can feel like a vast and unforgiving desert, leaving patients struggling to breathe and live their lives to the fullest. This research examines the potential of roflumilast, a selective phosphodiesterase 4 inhibitor, as a new treatment option for patients with severe COPD. The study analyzed data from several large-scale clinical trials, finding that roflumilast improved lung function and reduced exacerbations in patients with more severe COPD. This research offers hope for those struggling with COPD, providing a potential oasis of relief in the desert of their condition. The study also highlighted the importance of personalized treatment approaches, tailoring therapy to individual patient needs, like navigating a desert by considering the unique terrain and resources available.

A New Hope in the Desert of COPD

This research highlights the potential of roflumilast as a valuable treatment option for patients with severe COPD. The study's findings offer a beacon of hope in the desert of their condition, suggesting a potential for improved quality of life and a reduction in exacerbations. The study's emphasis on personalized treatment approaches underscores the importance of tailoring therapy to individual patient needs.

Finding Relief in the Desert of COPD

This research provides valuable insights into the potential of roflumilast for patients with COPD. The study's findings suggest that roflumilast can improve lung function and reduce exacerbations, providing a potential oasis of relief in the desert of their condition. The research encourages a personalized approach to treatment, considering the unique needs of each patient and tailoring therapy accordingly.

Dr.Camel's Conclusion

This research offers a glimmer of hope in the desert of COPD, highlighting the potential of roflumilast as a promising treatment option. It's a reminder that even in the face of challenging conditions, there are pathways to relief and a more fulfilling life.

Date :
  1. Date Completed 2010-11-22
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20689641

DOI: Digital Object Identifier

PMC2915539

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.